Uses of Oseltamivir: - Influenza (flu) Influenza Hypersensitivity. Severe renal impairment.

Respiratory viral infections (Influenza)

Oseltamivir is a prodrug of oseltamivir carboxylate. Oseltamivir carboxylate inhibits neuraminidase (sialidase), a viral surface enzyme which is responsible for the replication and infectivity of influenza virus A and B, thereby preventing the release of viruses from infected cells.

How to use Oseltamivir: Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Oseltamivir may be taken with or without food, but it is better to take it at a fixed time. Administration: May be taken with or without food. May be taken w/ meals to reduce GI discomfort. Cap may be opened & mixed w/ sweetened food products eg chocolate syr, sweetened condensed milk, apple sauce or yogurt. Swallow mixture immediately after preparation. Adult Dose: Oral Treatment of Influenza A and B Adult: 75 mg bid for 5 days. Initiate w/in 2 days of onset of symptoms. Prophylaxis of influenza A and B Adult: 75 mg once daily for at least 10 days. Initiate w/in 2 days of exposure. For community outbreak: May continue dosing for up to 6 wk. Child Dose: Influenza A and B Treatment <2 weeks: Safety and efficacy not established for treatment Aged 2 weeks to <1 year 3 mg/kg PO BID x5 days >1 year <15 kg: 30 mg PO q12hr x5 days 15-23 kg: 45 mg PO q12hr x5 days 23-40 kg: 60 mg PO q12hr x5 days >40 kg: 75 mg PO q12hr x5 days Dosing considerations Start within 24-48 hours of symptom onset Influenza A and B Prophylaxis <1 year: Safety and efficacy not established for prophylaxis ?1 year <15 kg: 30 mg PO qDay x10 days 15-23 kg: 45 mg PO qDay x10 days 23-40 kg: 60 mg PO qDay x10 days >40 kg: 75 mg PO qDay x10 days Dosing considerations Start within 2 days of exposure Renal Dose: Renal impairment: Haemodialysis patient: 30 mg after each dialysis session. Peritoneal dialysis patient: 30 mg as a single dose. CrCl (ml/min) Dosage Recommendation <10 Not recommended. >10-30 30 mg once daily. >30-60 30 mg bid.

May potentially inhibit replication of influenza virus in live/attenuated influenza virus vaccine.

Hypersensitivity. Severe renal impairment.

Common - Nausea - Vomiting - Abdominal pain - Diarrhea 1-10% Abdominal pain,Conjunctivitis,Ear disorder,Epistaxis,Insomnia,Nausea,Vomiting,Vertigo <1% Aggravation of diabetes,Anemia,Arrhythmia,Confusion,Delirium,Hemorrhagic colitis,Hepatitis,Humerus fracture,Peritonsillar abscess,Pneumonia,Pseudomembranous colitis,Pyrexia,Rash,Seizure,Transaminases increased,Toxic epidermal necrolysis,Unstable angina,Swelling of face or tongue Potentially Fatal: Anaphylaxis, severe dermatologic reactions.

Pregnancy Category C: There are insufficient human data upon which to base an evaluation of risk of Oseltamivir Phosphate to the pregnant woman or developing fetus.Nursing Mothers: It is not known whether oseltamivir or oseltamivir carboxylate is excreted in human milk. Oseltamivir Phosphate should, therefore, be used only if the potential benefit for the lactating mother justifies the potential risk to the breast-fed infant.

Precaution: Patient w/ resp disease, chronic cardiac disease. Renal and severe hepatic impairment. Immunocompromised patient. Childn. Pregnancy and lactation. Monitoring Parameters Monitor closely for signs and symptoms of behavioural changes. Lactation: Unknown; use caution

At present there has been no experience of over dose. Single dose of up to 1000 mg of Oseltamivir have been associated with nausea and/or vomiting.

Store at 25°C. Reconstituted susp: Store between 2-8°C for up to 17 days or at 25°C for up to 10 days. Do not freeze.

Respiratory viral infections (Influenza)

Oseltamivir is a prodrug of oseltamivir carboxylate (OC). OC is a potent selective competitive inhibitor of neuraminidase (an enzyme required for viral replication) of the influenza virus A and B. It prevents the release of viruses from infected host cell.

Pregnancy Category C: There are insufficient human data upon which to base an evaluation of risk of Oseltamivir Phosphate to the pregnant woman or developing fetus.Nursing Mothers: It is not known whether oseltamivir or oseltamivir carboxylate is excreted in human milk. Oseltamivir Phosphate should, therefore, be used only if the potential benefit for the lactating mother justifies the potential risk to the breast-fed infant.